Lilly's Q3 revenue and earnings miss primarily stemmed from lower-than-expected sales of Mounjaro and Zepbound. Should ...

Distributors were still working through new supplies purchased in the prior quarter rather than ordering more, Lilly said.

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

It's shaping up to be a tough period for Eli Lilly and Company , which a week ago released some disappointing third-quarter ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long struggling to ...

LLY had $11.4 billion in revenue for the quarter (up 20% versus Q3 figures from last year), with a net income of $970 million ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

The Indianapolis-based drugmaker missed expectations on sales of two popular drugs, diabetes treatment Mounjaro and ...

Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to ...